Neostigmine
Brand names: Neostigmine Methylsulfate
Neostigmine is an anticholinesterase used chiefly to reverse non-depolarising neuromuscular blockade at the end of anaesthesia, and also in conditions such as myasthenia gravis and post-operative ileus or urinary retention.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It reversibly inhibits acetylcholinesterase, increasing acetylcholine concentration at the neuromuscular junction and at muscarinic sites, thereby restoring transmission across the blocked junction.
Prescribing in practice
- Its muscarinic effects (bradycardia, bronchoconstriction, increased secretions, salivation) require co-administration of an antimuscarinic such as glycopyrrolate or atropine.
- It is ineffective and may be hazardous if given before some recovery of the block has occurred (it will not reverse a profound or deepening block).
- It does not reverse depolarising (suxamethonium) blockade and may prolong it.
Monitoring
Monitor heart rate, neuromuscular recovery (train-of-four), and adequacy of ventilation during and after reversal.
Counselling the patient
- This medicine is given by the anaesthetic team to help your muscles and breathing recover after surgery.
- Increased saliva or a slow heartbeat can occur briefly and is managed by the team.
Evidence & guidelines
Use reflects established anaesthetic and neuromuscular practice; consult current prescribing references and the SPC.
Reference: AAGBI Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH